ATE528015T1 - Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür - Google Patents

Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür

Info

Publication number
ATE528015T1
ATE528015T1 AT03726007T AT03726007T ATE528015T1 AT E528015 T1 ATE528015 T1 AT E528015T1 AT 03726007 T AT03726007 T AT 03726007T AT 03726007 T AT03726007 T AT 03726007T AT E528015 T1 ATE528015 T1 AT E528015T1
Authority
AT
Austria
Prior art keywords
methods
mammal
endothelial cells
prolifering
application
Prior art date
Application number
AT03726007T
Other languages
English (en)
Inventor
Ralph Reisfeld
Andreas Niethammer
Rong Xiang
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE528015T1 publication Critical patent/ATE528015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03726007T 2002-03-02 2003-02-28 Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür ATE528015T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/090,183 US7094410B2 (en) 2002-03-02 2002-03-02 DNA vaccine against proliferating endothelial cells and methods of use thereof
PCT/US2003/006256 WO2003073995A2 (en) 2002-03-02 2003-02-28 Dna vaccine against proliferating endothelial cells and methods of use thereof.

Publications (1)

Publication Number Publication Date
ATE528015T1 true ATE528015T1 (de) 2011-10-15

Family

ID=27787599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726007T ATE528015T1 (de) 2002-03-02 2003-02-28 Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür

Country Status (19)

Country Link
US (3) US7094410B2 (de)
EP (1) EP1487482B1 (de)
JP (1) JP4598401B2 (de)
KR (1) KR100979898B1 (de)
CN (1) CN1293917C (de)
AT (1) ATE528015T1 (de)
AU (1) AU2003228229B2 (de)
BR (1) BRPI0308103B8 (de)
CA (1) CA2477406C (de)
CY (1) CY1112663T1 (de)
DK (1) DK1487482T3 (de)
ES (1) ES2371870T3 (de)
MX (1) MXPA04008468A (de)
PL (1) PL213364B1 (de)
PT (1) PT1487482E (de)
RU (1) RU2318019C2 (de)
SI (1) SI1487482T1 (de)
WO (1) WO2003073995A2 (de)
ZA (1) ZA200406988B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595548A3 (de) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-Neovaskulatur Präparationen zur Krebsbehandlung
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
KR100614220B1 (ko) 2004-11-08 2006-08-21 고려대학교 산학협력단 Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
WO2010078675A1 (zh) * 2008-12-30 2010-07-15 陕西北美基因股份有限公司 多糖金磁复合微粒载药体及其制备方法
EP2403935B1 (de) * 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Zusammensetzungen mit angiogenen faktoren und verwendungsverfahren dafür
US9492523B2 (en) 2011-12-09 2016-11-15 The Board Of Regents For Oklahoma State University Broadly protective Shigella vaccine based on type III secretion apparatus proteins
DK2794849T3 (da) * 2011-12-22 2017-11-06 Vaximm Ag Fremgangsmåde til fremstilling af svækkede salmonellastammer med højt udbytte
RU2636348C2 (ru) 2012-07-05 2017-11-22 Ваксимм Аг Днк-вакцина для применения у пациентов с раком поджелудочной железы
US10543261B2 (en) 2012-08-31 2020-01-28 Osaka University DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope
US10548962B2 (en) 2012-10-22 2020-02-04 The Board Of Regents For Oklahoma State University Use of the salmonella SPP type III secretion proteins as a protective vaccination
US9950053B2 (en) 2012-10-22 2018-04-24 The Board Of Regents For Oklahoma State University Use of the Salmonella SPP type III secretion proteins as a protective vaccination
US20180153976A1 (en) 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
EP3626262B1 (de) 2015-06-18 2024-10-23 Vaximm AG Auf vegfr-2 abzielender dna-impfstoff zur kombinationstherapie
RU2759227C2 (ru) * 2020-04-10 2021-11-11 Генетик Диагностикс Энд Терапи 21 Лтд ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
EP1728865A1 (de) * 1998-09-04 2006-12-06 Aventis Pasteur Limited Behandlung von Gebärmutterhalskrebs
CA2414926A1 (en) 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof

Also Published As

Publication number Publication date
PL372314A1 (en) 2005-07-11
AU2003228229A1 (en) 2003-09-16
EP1487482B1 (de) 2011-10-12
BRPI0308103B8 (pt) 2021-05-25
CA2477406C (en) 2013-10-29
CN1293917C (zh) 2007-01-10
DK1487482T3 (da) 2011-12-05
US20070059323A1 (en) 2007-03-15
CY1112663T1 (el) 2016-02-10
BRPI0308103B1 (pt) 2019-02-19
US8048428B2 (en) 2011-11-01
CN1649622A (zh) 2005-08-03
BR0308103A (pt) 2005-01-04
US20030185802A1 (en) 2003-10-02
MXPA04008468A (es) 2004-12-06
CA2477406A1 (en) 2003-09-12
PL213364B1 (pl) 2013-02-28
EP1487482A4 (de) 2006-04-12
AU2003228229B2 (en) 2008-03-06
WO2003073995A2 (en) 2003-09-12
ZA200406988B (en) 2005-11-30
US20120039931A1 (en) 2012-02-16
JP2005519092A (ja) 2005-06-30
RU2318019C2 (ru) 2008-02-27
KR100979898B1 (ko) 2010-09-06
PT1487482E (pt) 2011-12-29
RU2004129332A (ru) 2005-05-27
US7094410B2 (en) 2006-08-22
EP1487482A2 (de) 2004-12-22
ES2371870T3 (es) 2012-01-10
US8241637B2 (en) 2012-08-14
JP4598401B2 (ja) 2010-12-15
KR20040088573A (ko) 2004-10-16
WO2003073995A3 (en) 2003-11-20
SI1487482T1 (sl) 2012-01-31

Similar Documents

Publication Publication Date Title
ATE528015T1 (de) Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür
NZ613809A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
WO2003061591A3 (en) Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
AR074501A1 (es) Oligonucleotidos inmunoestimuladores
BRPI0507169A (pt) polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
IL171966A0 (en) Prostate stem cell antigen variants and pharmaceutical compositions based thereon
ATE514433T1 (de) Nucleotid und zelluläre vakzine-zusammensetzung
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
FI1897548T4 (fi) T-solujen säätely
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
NO20055209D0 (no) Peptabody for cancerbehandling
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
WO2007149518A3 (en) Dna composition against tumor stromal antigen fap and methods of use thereof
JP2008512491A5 (de)
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
WO2005077048A3 (en) Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
DE60238044D1 (de) Tumortherapie mit vektoren auf sindbis virus-basis
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487482

Country of ref document: EP